Nanomedicines for Nucleic Acid Delivery
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".
Deadline for manuscript submissions: 30 September 2024 | Viewed by 2333
Special Issue Editors
Interests: gene therapy; controlled drug delivery; retinal gene therapy; nonviral vectors; lipid nanoparticles; ocular drug delivery; bioavailability; pharmacokinetics; formulations; nanoparticles drug delivery; pharmacology; nanomedicine; nanotechnology; bioequivalence studies; messenger RNA; therapeutic nucleic acids; lysosomal storage diseases
Special Issues, Collections and Topics in MDPI journals
Interests: pharmaceutics and pharmaceutical technology; controlled drug delivery; drug formulation development; nanotechnology in drug delivery; pharmaceutical research and development; ocular drug delivery; novel drug delivery systems; gene therapy; retinal gene therapy; nonviral vectors; lipid nanoparticles; messenger RNA; therapeutic nucleic acids; lysosomal storage diseases
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Gene therapy medicinal products are making great progress, leading the way in the development of advanced therapies. Diverse molecules are being used to address the development of this kind of medicines. DNA and messenger RNA (mRNA) induce protein expression, whereas small interfering RNA (siRNA), microRNA, oligonucleotides or aptamers provide posttranslational gene silencing. Molecular scissor and gene editing approaches, such as clustered regularly interspaced short palindromic repeats (CRISPR)-associated nuclease Cas9 (CRISPR/Cas9), are also being developed.
Thanks to the first messenger RNA-based vaccines marketed for COVID-19, nucleic acid-based medicines have recently taken a huge step toward the clinic. Nevertheless, the clinical application of nucleic acids is mostly limited by their instability and their difficulty to pass through the cellular membrane, due to the anionic nature of nucleic acids. The formulation of nucleic acids into nanosystems or vectors tailored to the type of nucleic acid and the therapeutic target is of major importance for advancing in the development of gene therapy.
This Special Issue aims to highlight the current state and future perspectives in the research area of nanomedicines for nucleic acid delivery. It will be focused on innovative delivery systems for plasmid DNA, mRNA, microRNA, aptamers, oligonucleotides, siRNA or gene editing strategies, including the study of their biodistribution at intracellular level, and the evaluation of their efficacy in vivo, ex vivo, and in vitro.
Prof. Dr. María Ángeles Solinís
Prof. Dr. Ana Del Pozo-Rodríguez
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- nanomedicine
- nanoparticles
- gene therapy
- DNA
- messenger RNA
- microRNA
- oligonucleotide
- siRNA
- CRISPR/Cas9
- intracellular biodistribution
